Innovation and Product Development news (page 4)

• 

  9 December 2025

  Roche's Gazyva Approved by EU for Lupus Nephritis

  Gazyva, combined with MMF, shows superior results in treating lupus nephritis, potentially delaying end-stage kidney disease, based on phase II and III studies.
• 

  9 December 2025

  Roche Introduces CE-Marked PCR Test for Accurate Vaginitis Diagnosis

  The new PCR test improves vaginitis diagnosis by detecting bacteria and yeast, using a single swab for faster, accurate results, enhancing healthcare efficiency.
• 

  9 December 2025

  Brenntag Secures Two German Sustainability Awards

  Brenntag's climate efforts earn German Sustainability and Transformation Awards, highlighting their carbon management, renewable energy use, and CO₂-emission-free site in Austria.
• 

  9 December 2025

  Johnson & Johnson's Phase 3 Study: TECVAYLI® and DARZALEX FASPRO® Show Promise for Relapsed/Refractory Multiple Myeloma

  TECVAYLI® plus DARZALEX FASPRO® reduces disease progression risk by 83% in RRMM patients, showing improved survival and quality of life over standard care.
• 

  9 December 2025

  Croda Partners with Amino to Enhance Biopharma Capabilities

  The partnership boosts global supply of high-purity amino acids for pharmaceuticals, enhancing product development and efficiency in biomanufacturing.
• 

  9 December 2025

  Borealis and Borouge Introduce Recleo: Cost-Effective Recycled Polyolefins

  Recleo offers a global portfolio of recycled polyolefins, enhancing sustainability and meeting regulatory targets with consistent quality and reliable supply.

• 

  9 December 2025

  Topsoe and Carbon Neutral Fuels Collaborate on e-SAF Project with SOEC Technology

  Project Starling in the UK will use SOEC technology to produce 25,000 tons of e-SAF annually, aiming for an 89% emissions reduction. Construction starts in 2028, operations by 2031.
• 

  9 December 2025

  Asahi Kasei Wins 2025 TSMC Award for PIMEL™ in Advanced Packaging

  Award highlights innovation in Advanced Packaging materials, with focus on PIMEL™ and AI applications, as part of Asahi Kasei's strategic plan for 2025–2027.
• 

  8 December 2025

  Air Products and Yara Negotiate Low-Emission Ammonia Projects Partnership

  Projects in the U.S. and Saudi Arabia aim for low-emission ammonia production, with investment decisions by 2026 and completion by 2030.
• 

  8 December 2025

  Yara Advances US Ammonia Strategy with Air Products Partnership

  Yara plans US ammonia projects to boost European competitiveness, aligning with capital policy. Final investment decision expected mid-2026.
• 

  8 December 2025

  Roche's Lunsumio Shows Promise in Early Lymphoma Treatment

  Lunsumio, combined with lenalidomide or Polivy, shows potential in treating relapsed or refractory lymphomas, offering outpatient, chemotherapy-free options.
• 

  8 December 2025

  Genmab Reports Promising Epcoritamab Data for Richter Transformation Treatment

  Epcoritamab shows high response rates and potential as monotherapy and in combination for treating Richter Transformation, with manageable side effects.
• 

  8 December 2025

  TechnipFMC Delivers 100th Subsea 2.0 Tree to Shell

  The 100th Subsea 2.0 tree, made in Malaysia, will be used in the Gulf of America. The platform's modular design reduces lead time and enhances efficiency in subsea operations.
• 

  8 December 2025

  BASF Launches Low-VOC Catalyst Lupragen N 208

  Lupragen N 208, a reactive amine catalyst, reduces VOC emissions in PU foams, meeting strict standards for applications like mattresses and automotive interiors.
• 

  8 December 2025

  TotalEnergies and NEO NEXT Merge to Form UK's Largest Independent Oil and Gas Producer

  TotalEnergies holds 47.5% in NEO NEXT+, enhancing synergies and cash flow with a diverse asset portfolio, producing over 250,000 barrels daily by 2026. Completion expected in H1 2026.
• 

  8 December 2025

  Evonik Releases EPDs for Building Protection Products

  EPDs for PROTECTOSIL® products offer transparency on environmental impact, aiding construction decisions and aligning with future regulatory requirements.
• 

  8 December 2025

  Boehringer Ingelheim Advances Triple-Agonist Peptide for Obesity Treatment

  BI 3034701 shows promise in Phase I for obesity treatment, demonstrating safety and weight loss, advancing to mid-stage development.
• 

  8 December 2025

  RWE Upgrades Lasbek Wind Farm: Fewer Turbines, Higher Output

  Four new turbines replace six old ones, boosting capacity to power 18,000 homes. Rotor blades repurposed for noise barriers. Local municipalities gain €100,000 more annually.
• 

  8 December 2025

  HydroThane Revamps Leadership to Boost Growth

  New leadership aims to enhance partnerships, expand markets, and focus on sustainable projects, leveraging Axens' support and global reach.
• 

  8 December 2025

  Covestro and Allmed Explore Recycling Artificial Kidney Filters

  A study aims to recycle polycarbonate from kidney filters, creating a circular economy model for medical devices with partners in the UK.
• 

  7 December 2025

  Genmab's Phase 3 Trial Shows EPKINLY + R2 Benefits in Relapsed Follicular Lymphoma

  EPKINLY + R2 reduces disease progression risk by 79% in relapsed follicular lymphoma, with a 95% response rate. FDA-approved, it offers a new second-line treatment option.
• 

  7 December 2025

  Toray Develops Technology for 95% Lithium Recovery from Batteries

  New nanofiltration membrane efficiently recovers lithium from used batteries, enhancing recycling and supporting closed-loop systems for electrified vehicles.
• 

  6 December 2025

  Genmab Reports Epcoritamab Trials Show Remission in DLBCL and FL

  Epcoritamab shows high response rates in DLBCL and FL trials, with promising results in elderly patients and manageable side effects.
• 

  6 December 2025

  Protagonist and Takeda: Rusfertide's Long-Term Efficacy in Polycythemia Vera

  Rusfertide shows sustained hematocrit control and reduced phlebotomy need in polycythemia vera over 52 weeks, with a consistent safety profile.
• 

  6 December 2025

  Johnson & Johnson's CARVYKTI® Shows 2.5-Year Remission in Early Myeloma Treatment

  CARVYKTI® offers 80% of standard-risk myeloma patients lasting remission after a single infusion, with improved outcomes when used early.
• 

  5 December 2025

  Johnson & Johnson's INLEXZO™ Shows 74% One-Year Disease-Free Survival in High-Risk NMIBC

  New data shows high survival rates and bladder preservation in BCG-unresponsive NMIBC patients using gemcitabine intravesical system, with minimal severe side effects.
• 

  5 December 2025

  Ercros Joins Aragon's Circlear Circular Economy Cluster

  Circlear, part of the Redol project, aims to enhance collaboration for sustainable practices in Aragón, with Ercros as a founding member.
• 

  5 December 2025

  Veolia and Science City Guangzhou Launch Decarbonization Project in China

  The project captures industrial flue gas, converting waste heat into energy, reducing 200,000 tons of carbon annually, and aligns with China's green development goals.
• 

  4 December 2025

  Moeve and Mistral AI Partner on Generative AI for Energy Sector

  They will develop a pilot digital assistant to enhance energy efficiency, productivity, and sustainability in industrial centers, supporting Europe's technological sovereignty.
• 

  4 December 2025

  Merck's EXZOLT CATTLE-CA1 Conditionally Approved by FDA for Screwworm and Tick Control

  EXZOLT CATTLE-CA1, a new isoxazoline pour-on, is conditionally approved for screwworm and cattle fever tick control, with a 98-day meat withdrawal period. Available by prescription in 2026.